We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+0.13%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$181M
AUM Growth
+$11.9M
(+7%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
7.34%
Top 10 Holdings %
Top 10 Hldgs %
90.13%
Holding
15
New
3
Increased
4
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$15.3M |
| 2 |
GSK
GSK
|
+$9.96M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$7.96M |
| 4 |
United Therapeutics
UTHR
|
+$2.11M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$1.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$16.7M |
| 2 |
Exelixis
EXEL
|
+$3.11M |
| 3 |
Cardinal Health
CAH
|
+$2.56M |
| 4 |
Alkermes
ALKS
|
+$989K |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$665K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Exelixis
EXEL
$13.3B
| $32.4M | 17.93% |
878,533
-87,333
| -9% | -$3.11M |
|
|
2
United Therapeutics
UTHR
$25.8B
| $30.3M | 16.74% |
98,228
+6,171
| +7% | +$2.11M |
|
|
3
Cardinal Health
CAH
$53.9B
| $26M | 14.38% |
188,745
-20,100
| -10% | -$2.56M |
|
|
4
Supernus Pharmaceuticals
SUPN
$2.59B
| $14.1M | 7.82% |
+431,986
| New | +$15.3M |
|
|
5
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.5M | 6.91% |
100,703
-5,100
| -5% | -$665K |
|
6
Enanta Pharmaceuticals
ENTA
$366M
| $11.7M | 6.46% |
2,116,586
-804
| -0% | -$4.97K |
|
|
7
GSK
GSK
$104B
| $10.5M | 5.83% |
+272,000
| New | +$9.96M |
|
8
Indivior Pharmaceuticals
INDV
$4.73B
| $9.2M | 5.09% |
965,368
+29,688
| +3% | +$312K |
|
9
Sanofi
SNY
$103B
| $8.27M | 4.57% |
149,096
-100
| -0.1% | -$5.41K |
|
10
BioNTech
BNTX
$22.9B
| $7.97M | 4.41% |
87,563
-1,100
| -1% | -$123K |
|
|
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
| $7.44M | 4.11% |
+950,000
| New | +$7.96M |
|
|
12
Alkermes
ALKS
$8.22B
| $6.86M | 3.79% |
207,822
-30,314
| -13% | -$989K |
|
|
13
Vanda Pharmaceuticals
VNDA
$307M
| $3.46M | 1.91% |
754,381
+375,619
| +99% | +$1.75M |
|
|
MURA
14
DELISTED
Mural Oncology
MURA
| $89K | 0.05% |
70,263
+100
| +0.1% | +$365 |
|
|
15
Biogen
BIIB
$30B
| – | – |
-108,923
| Closed | -$16.7M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Krensavage Asset Management held 15 positions worth $181M, up 7% from $169M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Krensavage Asset Management deployed $13.3M of net new capital in Q1 2025, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Supernus Pharmaceuticals: 431,986 shares worth $14.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Exelixis, an estimated $3.11M trimmed.
- Krensavage Asset Management's largest Q1 2025 buy was Supernus Pharmaceuticals: 431,986 shares worth $14.1M.
- Krensavage Asset Management added most to United Therapeutics in Q1 2025, an estimated $2.11M increase.
- Krensavage Asset Management's biggest Q1 2025 reduction was Exelixis, cutting an estimated $3.11M.
- Krensavage Asset Management fully exited Biogen in Q1 2025, selling an estimated $16.7M.
- Krensavage Asset Management's ten largest holdings make up 90% of its $181M portfolio in Q1 2025.
- Krensavage Asset Management opened 3 new positions and closed 1 in Q1 2025.
- Krensavage Asset Management's portfolio value rose 7% quarter-over-quarter to $181M.
Based on Krensavage Asset Management's 13F filing for Q1 2025, filed 15 May 2025.